Featured Research

from universities, journals, and other organizations

Tumor Suppressor Genes Predict Bladder Cancer Future

Date:
March 18, 2004
Source:
Baylor College Of Medicine
Summary:
The presence of two mutated genes in bladder cancer tumors indicates there is a high risk that the cancer will continue grow and spread, said a Baylor College of Medicine (BCM) researcher in a report released in the March 15 issue of the Journal of Clinical Oncology.

The presence of two mutated genes in bladder cancer tumors indicates there is a high risk that the cancer will continue grow and spread, said a Baylor College of Medicine (BCM) researcher in a report released in the March 15 issue of the Journal of Clinical Oncology.

One of the mutated proteins – p53 – is a tumor suppressor that in its normal form prevents cell changes that can lead to cancer. When p53 binds to DNA is stimulates another gene to produce p21. Then p21 interacts with a protein that stimulates cell division. When p21 is in a complex with this protein, the cell cannot go through the next stage of division. Mutations in the genes prevent these protective mechanisms.

In this study, Dr. Seth Lerner, associate professor urology at BCM, evaluated the roles of four gene alterations in the tumors of 80 bladder cancer patients. They found that one of the genes was altered in 83 percent of patients.

However, p53 proved the strongest predictor that the cancer would progress and p21 was the next strongest. This indicates that these genes play an important role in the development of this disease and should be more closely studied, said Lerner in his paper.

Others who participated in the study came from the Methodist Hospital in Houston, The University of Texas M.D. Anderson Cancer Center, Houston; and The University of Texas Southwestern Medical Center, Dallas, TX.


Story Source:

The above story is based on materials provided by Baylor College Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Baylor College Of Medicine. "Tumor Suppressor Genes Predict Bladder Cancer Future." ScienceDaily. ScienceDaily, 18 March 2004. <www.sciencedaily.com/releases/2004/03/040317073445.htm>.
Baylor College Of Medicine. (2004, March 18). Tumor Suppressor Genes Predict Bladder Cancer Future. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/03/040317073445.htm
Baylor College Of Medicine. "Tumor Suppressor Genes Predict Bladder Cancer Future." ScienceDaily. www.sciencedaily.com/releases/2004/03/040317073445.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins